NCT02121483 - Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

empagliflozin medium dose

DRUG

empagliflozin high dose

DRUG

empagliflozin low dose

Trial Locations (11)

1245.87.01013 Boehringer Ingelheim Investigational Site, New Haven

1245.87.01004 Boehringer Ingelheim Investigational Site, Boston

1245.87.01002 Boehringer Ingelheim Investigational Site, Toledo

1245.87.01012 Boehringer Ingelheim Investigational Site, Philadelphia

1245.87.01001 Boehringer Ingelheim Investigational Site, Pittsburgh

1245.87.33001 Boehringer Ingelheim Investigational Site, Lyon

1245.87.97202 Boehringer Ingelheim Investigational Site, Beersheba

1245.87.97203 Boehringer Ingelheim Investigational Site, Tel Litwinsky

1245.87.52001 Boehringer Ingelheim Investigational Site, Chihuahua City

1245.87.27003 Boehringer Ingelheim Investigational Site, Bellville

1245.87.27002 Boehringer Ingelheim Investigational Site, Pretoria